Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing.
References:
[1]. Meredith McKean, et al. Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors.
















